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ORIGINAL ARTICLE
Sensitivity to Change of Patient-Preference
Measures for Pain in Patients With Knee
Osteoarthritis: Data From Two Trials
MATTHEW J. PARKES,1 MICHAEL J. CALLAGHAN,1 TERENCE W. O’NEILL,2 LAURA M. FORSYTHE,1
MARK LUNT,1 AND DAVID T. FELSON3
Objective. In osteoarthritis (OA) clinical trials, a pain measure that is most sensitive to change is considered optimal.
We compared sensitivity to change of patient-reported pain outcomes, including a patient-preference measure (where
the patient nominates an activity that aggravates their pain).
Methods. We used data from 2 trials of patients with confirmed (American College of Rheumatology criteria) knee
OA: a trial of brace treatment for patellofemoral OA, and a trial of intraarticular steroids in knee OA. Both trials
reported an improvement in pain following treatment. Participants rated pain on a 100-mm visual analog scale (VAS),
in the activity that caused them the most knee pain (VASNA), as well as completing questions on overall knee pain
and the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) scores were also calculated from the KOOS. Standardized changes in each out-
come were generated between treatment and control after 6 weeks intervention in the BRACE trial, and 1–2 weeks
following intervention in the steroid trial.
Results. The VASNA produced standardized changes following treatment that were at least as large as other pain outcomes.
In the BRACE trial, the between-groups standardized change with the VASNA was20.63, compared with the KOOS pain sub-
scale change of 20.33, and pain in the last week VAS change of 20.56. In the steroid study, within-group change following
treatment in the VASNA was 20.60, compared to the last week VAS change of 20.51, and KOOS pain subscale change of
20.58.
Conclusion. Pain on nominated activity appears to be at least as, and in some cases more, sensitive to change than
the KOOS/WOMAC questionnaire.
INTRODUCTION
Pain is an outcome that is of particular interest to
researchers in osteoarthritis (OA); it is highly clinically
relevant and relatively easy to measure. For these reasons,
pain is one outcome commonly collected in OA trials. The
most commonly used outcome measure is the Western
Ontario and McMaster Universities Osteoarthritis Index
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(WOMAC) (1,2). However, while data on pain may be col-
lected in most OA clinical trials, the instruments selected
to collect such data vary widely (3).
Self-reported pain is often assessed via a single-item
index, e.g., a numerical rating scale (NRS) from 0–10 that
rates pain in the last 24 hours. Alternatively, multi-item
questionnaires, such as the WOMAC and Knee Injury and
Osteoarthritis Outcome Score (KOOS), can be used; these
measures ask several questions on various aspects of pain in
order to calculate a composite overall pain score. The ques-
tions used in multi-item measures are typically fixed and
inflexible between patients. This rigidity in wording allows
the individual patient scores to be compared easily between
patients, since they all answer the same question(s). Howev-
er, there are limitations caused by fixing the question word-
ing in this way. In a multi-item measure, asking many
correlated questions (for example, rating pain in a range of
different activities) in an attempt to provide a more compre-
hensive assessment gathers much more data. However, this
is offset by the fact that 1) these questionnaires take longer to
administer than a single-item measure, and 2) there is a risk
that many items may be irrelevant to the patient. In theory,
irrelevant items will change less following an intervention
than more salient ones, and therefore the sensitivity of a tool
to detect change will be moderated by the relevancy of the
questions asked.
Of single-item approaches to assessing outcome in OA, an
approach that allows for individual variability could be
used. Such approaches might ask subjects, for example, to
nominate an activity that most aggravates their pain, and
then provides a rating score within that context (“Please
indicate how much pain you have in that activity”). Current
examples of such patient-preference measures include the
McMaster Toronto Arthritis Patient Preference Disability
Questionnaire (MACTAR) (4), the Patient-Specific Index (5),
and the Patient-Generated Index (6). To our knowledge,
with the exception of the MACTAR (7,8), which focuses on
patient function and not pain, patient-preference instru-
ments have not been evaluated in OA. We tested a single-
item version of a patient-preference questionnaire focused
on pain, i.e., the “pain on nominated activity visual analog
scale” (VASNA).
Comparisons of outcomes in trials in OA with regards to
sensitivity to change (9) have included a mixture of trials,
including those reporting a significant change and those
that have not. The difficulty in examining trials whereby a
treatment effect has not been established is that when an
instrument shows poor change following an intervention,
it is difficult to distinguish between an instrument with
poor responsiveness and a responsive instrument tested
when there is no treatment effect. Ideally, the sensitivity
to change of outcome measures should be examined in tri-
als showing a treatment effect.
To this end, we sought to characterize and compare pain
self-report outcomes, using data from 2 clinical trials in
patients with OA that reported a statistically significant pos-
itive change in 1 or more pain outcomes, in an attempt to
establish whether there was a difference between single-
and multi-item questionnaires, and particularly, whether a
patient-preference approach performed well with respect to
sensitivity to change.
PATIENTS AND METHODS
Trials from which data are drawn. Data from 2 inter-
ventional clinical trials on patients with knee OA were
used in this analysis. In both trials, eligible subjects had to
meet American College of Rheumatology criteria for knee
OA (10) and have moderate knee pain severity prior to tri-
al commencement. The BRACE trial (ISRCTN 50380458)
was a randomized controlled trial targeting persons with
painful patellofemoral OA where a patellar knee brace or
no brace was administered to participants, and persons
were followed for 6 weeks (11).
The TASK (Targeting Synovitis Knee Osteoarthritis) trial
(ISRCTN 07329370) was an open-label trial of persons with
painful knee OA monitoring response to intraarticular
methylprednisolone. Participants were assessed just prior
to treatment and approximately 1 week later (12).
Patients were asked to complete the KOOS questionnaire,
as well as 2 single-item, 100-mm VAS that rated pain in 2 sit-
uations: pain in the last week (VASlast week) and pain during
an activity nominated by the patient to be the most aggravat-
ing for their knee pain (VASNA). The TASK trial participants
were additionally asked to score a patient global assessment
on a 100-mm VAS (VASglobal). All VAS scores ranged from
0–100 (i.e., every millimeter), where 0 indicated no pain
at all and 100 indicated pain as bad as the patient could
possibly imagine. Both trials have reported a positive effect
Significance & Innovations
 To our knowledge, this article is the first to assess
the sensitivity of a patient-preference outcome mea-
sure, assessing pain in patients with knee osteoar-
thritis (OA).
 We find that the sensitivity of this novel outcome is
at least comparable, if not marginally superior to,
the Knee Injury and Osteoarthritis Outcome Score
and the Western Ontario and McMaster Universi-
ties Osteoarthritis Index. This is particularly useful,
as the novel outcome (the pain on nominated activi-
ty visual analog scale, [VASNA]) is only one simple
question.
 The VASNA also allows the collection of data on the
distributions of painful activities in different clini-
cal knee OA groups (we compare a mixed knee OA
population to a predominantly patellofemoral knee
OA population).
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(i.e., a statistically significant improvement) on pain
outcomes.
Variable definitions. The KOOS questionnaire is an
extension of the WOMAC questionnaire, which features the
original WOMAC items plus others. We derived WOMAC
scores from the patients’ completed KOOS questionnaires in
accordance with the scoring guidelines (13). This therefore
meant that both the KOOS and WOMAC were expressed on
a 0–100 scale, where 100 indicated no symptoms and 0 indi-
cated extreme symptoms. All other outcomes were complet-
ed directly by study participants.
To assess the magnitude of treatment effects, and to allow
comparison of effect sizes across outcomes with different
scales, we standardized all outcomes, converting them all to
have a mean of 0 and an SD of 1. The KOOS features a
reversed scoring system, where high scores indicate lower
pain rather than higher pain. We reversed the standardized
scores of the KOOS outcomes, meaning that greater stan-
dardized scores for all outcomes represent increased pain,
and lower standardized scores represent decreased pain.
Converting the outcomes to standard scores in this way
allows all outcomes to be incorporated into 1 common statis-
tical model, which in turn allows for statistical inferences
(significance tests) to be made between the outcomes. In
contrast, the more commonly used approach of simply
deriving effect sizes for each outcome (Cohen’s D) only
allows comparison of the magnitude of effect sizes without
formal statistical tests.
Analysis approach. Changes in standardized scores
were calculated between the treatment and control groups
in the BRACE trial at the 6-week followup visit. The TASK
trial featured an open-label design without a control group;
so the changes in standardized scores for this trial were cal-
culated for the treatment group alone, assessing the change
between the baseline and first followup visit after the inter-
vention was applied.
The initial aim was to compare the magnitude of changes
in each outcome. We used random-effects panel linear regres-
sion, with the standardized score at the followup visit as the
outcome (the 6-week visit for the BRACE controlled trial, and
the postinjection followup visit for the TASK trial), the
standardized score at the baseline visit as a covariate, and
outcome type (i.e., the scale, a categorical variable, which
was one of VASNA, VASlast week, KOOS pain subscale, KOOS
symptoms subscale, KOOS activities of daily living subscale,
WOMAC pain subscale, WOMAC stiffness subscale, or the
WOMAC function subscale, coded as dummy variables) as a
predictor variable. The KOOS sport and recreation and quali-
ty of life subscales were excluded from analyses, since many
participants in both trials left more than 2 items blank (often
more), precluding them from being scored in accordance
with the KOOS user guide (scoring was available for only 21
of 126 and 106 of 126 in BRACE, and 1 of 127 and 95 of
127 in TASK for sport and recreation and quality of life,
respectively). We used participant identifier as the panel
variable for the random-effects model. For the BRACE trial
analysis, we also included a predictor variable for treatment
Table 1. Baseline characteristics of patients from the BRACE and TASK trials*
BRACE
(n5 126)
TASK
(n5127)
Variable No. Statistic No. Statistic
Age, years 126 55.567.5 127 61.98610.32
Females, frequency (%) 126 72 (57.1) 127 63 (49.6)
BMI, kg/m2 126 31.065.7 – –
K/L grade, frequency
(% of observations)
88 – 115 –
1 2 (2.3) 0 (0.0)
2 34 (38.6) 43 (37.4)
3 52 (59.1) 64 (55.7)
4 0 (0.0) 8 (7.0)
VAS
Pain on nominated activity 125 6.56 2.1 122 6.661.8
Pain in last week 125 5.96 2.5 124 6.162.1
Global pain VAS – – 124 4.462.3
KOOS subscales
Pain 126 49.86 18.3 127 45.2615.1
Symptoms 126 50.26 16.6 126 48.3616.2
Activities of daily living 126 54.96 20.6 123 49.9618.1
WOMAC subscales
Pain 126 55.06 19.9 127 49.8617.5
Stiffness 126 46.26 20.3 126 39.8617.2
Function 123 55.66 20.3 119 50.2618.3
* Values are the mean6SD unless indicated otherwise. Descriptive statistics for the Knee Injury and Osteoar-
thritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),
and visual analog scales (VAS) are presented in their original scales (not standardized) for ease of interpreta-
tion. Two patients from the BRACE trial had Kellgren/Lawrence (K/L) grades of 1; they additionally had
arthroscopy reports prior to baseline, which confirmed osteoarthritic changes. BMI5 body mass index.
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group, and an interaction effect between the treatment group
and the outcome type.
For the 6-week treatment versus no treatment compari-
son, using BRACE data, the full random-effects model is
as follows:
yijk5mj1b1xij1bjk1ui1Wij
Where i5patient, j5outcome (e.g., WOMAC pain) (cod-
ed as dummy variables), k5 treatment, yij5 standardized
score at 6-week visit (for a given patient and outcome),
x5 standardized score at baseline, bjk5 outcome 3 treat-
ment group interaction, m5model intercept, ui5 subject-
level random effect, and Wij5 error.
The random-effects model for the TASK data is as
follows:
yij5m1Xij1b11Xij2bj21ui1Wij
Where yij5 standardized score at the postinjection followup
visit, Xij15 standardized score at baseline, Xij25 outcome
type (e.g., WOMAC pain) (coded as dummy variables),
ui5 subject,m5model intercept, and Wij5 error.
The nominated painful activities reported by participants
were collected in the form of a free-text field. We split
patients into subgroups based on their nominated activity
“themes,” and attempted to match these to WOMAC/KOOS
items to better understand the overlap between patient-
preference choices and these instruments.
Statistical analysis was undertaken using Stata (version
13.1). We used a significance level of 5% in all statistical tests.
RESULTS
Demographics. Baseline characteristics of patients from
the BRACE and TASK trial were generally similar (Table 1).
Patients in TASK were older, with generally more severe
OA as seen on radiographs, and had slightly more pain at
baseline, which corresponds with the different inclusion
criteria of the 2 trials.
Comparing change following intervention between
outcomes. Comparing the postintervention standardized
differences across the different outcomes, the VASNA had
the greatest standardized change following treatment in
the BRACE study (20.63) for the between groups analysis
(Figure 1). Knee pain in past week (also VAS) also showed a
high standardized change (20.56), and these were higher
than the standardized changes for KOOS pain (20.33) or
WOMAC pain (20.29). Standardized changes appeared
more consistent across outcomes in the TASK study than in
BRACE. In TASK, the VASNA tied for the greatest standard-
ized change with the WOMAC stiffness subscale (both had
standardized changes of20.60) (Figure 2). Subsequent pair-
wise comparisons between outcomes found few significant
differences between outcomes (see Supplementary Tables 1
and 2 for the BRACE and TASK trial pairwise comparisons,
respectively, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22823/
abstract).
Painful activities nominated by trial participants. A
total of 10 specific activity themes were reported by patients
Figure 1. Comparison of standardized change for different outcomes from the BRACE trial. Data
depicted refer to the between-groups difference in the standardized score at the 6-week followup visit
in each outcome, after controlling for baseline score. More negative effect sizes represent larger reduc-
tions in pain, and therefore greater sensitivity to change. Error bars indicate 95% confidence intervals
for each point estimate. VASNA5nominated activity visual analog scale; VASlast week5pain last week
rated on VAS; KOOS5Knee Injury and Osteoarthritis Outcome Score; ADL5 activities of daily liv-
ing; WOMAC5Western Ontario and McMaster Universities Osteoarthritis Index.
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in the BRACE and TASK trials (Table 2). Some activities
matched activities listed in KOOS and WOMAC, others had
no matches, and yet others had unclear matches. “Stairs”
was the most often reported activity aggravating partici-
pants’ knee pain, and the proportion cited was much greater
in BRACE (66.7%), a trial of patellofemoral OA, than in
TASK (39.7%). For stair climbing pain, 44% of TASK partici-
pants and 88% of the BRACE patients nominated pain either
going up or downstairs alone. Patients were asked to nomi-
nate an activity without prompting, and we interpreted
Figure 2. Comparison of standardized response means for different outcomes from the TASK trial.
Data depicted refers to the within-group change in standardized score at the 1-week followup visit
in each outcome, after controlling for baseline score. More negative effect sizes represent larger
reductions in pain, and therefore greater sensitivity to change. Error bars indicate 95% confidence
intervals for each point estimate. VASNA5nominated activity visual analog scale; VASlast week5pain
last week rated on VAS; KOOS5Knee Injury and Osteoarthritis Outcome Score; ADL5 activities of
daily living; WOMAC5Western Ontario and McMaster Universities Osteoarthritis Index.
Table 2. Comparison of painful activities nominated by patients in the BRACE and
TASK trials*
Nominated (patient-reported)
as most painful activity
BRACE
(n5 126)
TASK
(n5 126)
Closest-matched KOOS
pain subscale question
Stairs/inclines 84 (66.7) 50 (39.7) P6, going up or down stairs
Squatting/bending/kneeling 28 (22.2) 7 (5.6) None†
Sitting to standing 7 (5.6) 15 (11.9) None†
Prolonged sitting 3 (2.4) 4 (3.2) Closest: P8, sitting or lying
Walking 1 (0.8) 33 (26.2) P5, walking on a flat surface
Walking and stairs 1 (0.8) 1 (0.8) None
Running 1 (0.8) 1 (0.8) None
Kneeling and inclines 1 (0.8) 0 (0.0) None
Turning/twisting 0 (0.0) 5 (4.0) P2, twisting/pivoting on knee
Standing 0 (0.0) 2 (1.6) P9, standing upright
Other 0 (0.0) 8 (6.4) None
* Values are the frequency (% of the total study sample). For simplicity, the nominated activities reported
have been collapsed into more general categories (for example, patients reporting “going upstairs” only or
“going down inclines or slopes” only are both classified as “stairs/inclines”). “Other” activities reported
were “at night” (3), “at work” (1), “dancing” (1), “first thing in morning” (1), “in bed” (1), and “work” (1).
One patient did not complete the nominated activity question in the TASK trial at baseline, leaving a total of
126 patients for this outcome. KOOS5Knee Injury and Osteoarthritis Outcome Score.
† Squatting/bending/kneeling could overlap in KOOS with a question of pain when bending and straighten-
ing the knee, although our analyses showed little overlap of these elements among patients (those reporting
change in pain squatting/bending/kneeling in BRACE did not have similar change in the KOOS question).
Pain ongoing from sitting to standing could be mapped to pain with sitting or lying.
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those patients who cited only one direction when negotiat-
ing stairs as having pain that was unidirectional. The KOOS
and WOMAC pain questions ask about pain going either up
or down stairs, and do not differentiate between directions
(Table 3). We performed a further followup analysis that
included the KOOS items A1 and A2 (from the function sub-
scale, rather than pain), which do differentiate between
direction of stair travel, and found a greater correlation
between change in pain on the VASNA and change in func-
tion in these items when the direction of stair travel matched
(see Supplementary Tables 3 and 4, available on the Arthri-
tis Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22823/abstract). Another frequently
nominated painful set of activities was squatting and kneel-
ing, which again is not covered by the KOOS/WOMAC. Five
additional themes nominated by participants were clearly
not covered by the KOOS or WOMAC, and together these
themes made up 30.2% of the BRACE participants’ nominat-
ed activities, and 19.0% of the activities of TASK patients
(38 and 24 participants, respectively) (Table 2).
DISCUSSION
This study attempts to add to the literature on selecting
appropriate study outcomes by providing evidence on the
sensitivity to change of patient-reported outcomes in OA tri-
als with a special focus on a patient-preference measure. Out-
comes that are more sensitive to change are good candidates
as potential outcomes for future trials. Recent expert consen-
sus meetings have agreed upon the importance of standardiz-
ing outcomes in future OA trials, in an attempt to increase
validity and sensitivity, and reduce heterogeneity in trial
design, and therefore improving the accuracy of future meta-
analyses (14,15). The present study finds evidence of the
VASNA being more sensitive than other methods, especially
in a trial of patients with painful patellofemoral OA.
In both BRACE and TASK, the VASNA, a single question,
appeared to have sensitivity to change that at least equaled
that of the KOOS and WOMAC subscales, which are a
composite of several questions, on a range of activities. This
suggests that 1 single question, the “right” question for that
patient, is highly sensitive to change. With a fixed single item,
the question then becomes “which activity do we choose?”
The approach used by WOMAC/KOOS has a drawback:
asking more questions increases the risk of asking unneces-
sary questions that are irrelevant to a specific patient, and
that therefore do not change following intervention. In addi-
tion to including possibly irrelevant items, our findings sug-
gest that the KOOS/WOMAC miss items that participants
cite as more painful at least in the 2 trials investigated,
which suggests that the KOOS/WOMAC may need more
items to adequately cover commonly cited painful activities.
Alternative approaches with multiple questions exist, such
as the Patient-Reported Outcomes Measurement Informa-
tion System instruments or instruments using computer
adaptive technology (CAT). The premise behind these meth-
odologies (16) is that participants are asked selected,
increasingly targeted questions about activity-related pain
from a large bank of questions until a maximal level of preci-
sion is attained. While specific WOMAC or KOOS questions
may not have relevance to specific patients, we note that
both the KOOS and WOMAC were developed after exten-
sive discussions with patients with knee and hip OA to
identify activities that were often painful (17,18).
An alternative approach, used by the VASNA, is to include
a free-text item that allows participants to vary the context of
a question. All participants will still score pain throughout
the trial, but it allows the participant to give an individual-
ized response on pain in a framework (activity) appropriate
and relevant to their situation. Allowing a question to be
individualized by the patient may increase sensitivity to
change, without adding information on other, less relevant
activities.
Asking a single question has other advantages than simply
sensitivity/precision. While the activity themes reported in
both trials were broadly similar, the proportions in which
they were reported differed largely, with BRACE trial partic-
ipants citing stairs or inclines much more often than those
in the TASK trial. This is an unsurprising finding, given that
the BRACE trial’s inclusion criteria selected persons with
patellofemoral OA, whereas the TASK inclusion/exclusion
criteria allowed participants with more mixed disease. It
also suggests that using fixed instruments like the WOMAC
and KOOS for patellofemoral OA is likely to compromise
sensitivity to change, whereas this choice may be more rea-
sonable in trials of knee OA in general.
There are a number of possible advantages to this more
bottom-up approach of involving patients’ perspectives
directly in outcome measures in OA, as opposed to the top-
down method of the researcher deciding which questions
are best for the patient. It includes more of a patient’s view
directly in the study. Furthermore, it provides additional
data alongside a simple pain score, as patients also provide
qualitative data on the sorts of activities that are painful to
them, i.e., activities that might not otherwise have been con-
sidered. For example, we found many patients in both the
BRACE and TASK trials appear to find either going up or
going downstairs alone more aggravating to their pain,
which contrasts with many pain questionnaires that ignore
the direction of stair travel. A potential drawback to this
approach is that while it aims to maximize sensitivity to
detect a treatment effect, by selecting questions for activities
that are most painful, it risks ignoring those activities that
are most important to the patient’s activities of daily living.
Our analysis also included as a by-product an examina-
tion of the comparative sensitivity to change of a global knee
pain question (the VASlast week) versus the WOMAC/KOOS
pain scale. For the patellofemoral OA trial, the VASlast week
Table 3. Direction of painful stair travel indicated by
patients in the BRACE and TASK trials who nominated
“stairs/inclines” as their painful activity*
Stair direction
declared (if any)
BRACE
(total5 84)
TASK
(total5 50)
Downstairs only 44 (52.4) 14 (28.0)
Upstairs only 30 (35.7) 8 (16.0)
Bidirectional/not specified 10 (11.9) 28 (56.0)
* Values are the frequency (% of total study sample).
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was more sensitive to change than the KOOS/WOMAC, but
that was not the case for the TASK study. The difference in
VASlast week responsiveness between TASK and BRACE is
an interesting finding, and the reasons for this observation
are unclear. One possible explanation for this difference
could be the different samples used in each of the trials. The
TASK trial was comprised of subjects with mixed OA (not
one compartment specifically), unlike BRACE, which
selected patients with patellofemoral OA only. The KOOS
and WOMAC were specifically designed for use in mixed
disease contexts, and it may be that the patellofemoral
patients are not captured quite as well, hence the difference
between the 2 trials. Given that the other outcomes are fairly
consistent between BRACE and TASK, another possible
explanation is linked to the focus of BRACE on patello-
femoral OA versus TASK, which recruited a more general
group of patients with painful knee OA. Our data do not per-
mit us to conclude which of these alternative choices is like-
ly to be consistently more sensitive to change in OA trials.
Others have reported that a global pain question in a fixed
timeframe is more sensitive to change than the WOMAC
pain subscale (19,20) and other “complex” multi-item mea-
sures (21). The same trend has also been noted when compar-
ing a global function question versus the WOMAC function
subscale, with the single-item global question having supe-
rior sensitivity to change (22). In contrast, Dworkin et al in a
meta-analysis combining many single fixed item indices of
pain found that the WOMAC produced a greater standard-
ized change (23). This analysis, however, combined many
indices of pain and, as noted by the authors, it is unclear
whether the heterogeneity of both the included trials, and
the combination of outcomes used, may have contributed to
this conflicting trend.
This study is not without limitations. We specifically
selected only 2 studies for this analysis. It would be advanta-
geous to conduct this analysis across a greater number of tri-
als to confirm whether the trends we observed are consistent
across a range of trial types and OA populations. However,
an analysis of sensitivity to change is best conducted on a
trial whereby the researcher is (at least) reasonably sure that
a true treatment effect has occurred. It is difficult to selec-
tively search for OA trials that are 1) positive, i.e., observed a
true pain reduction, 2) in a mixture of OA subpopulations,
and 3) collected data and reported on multiple collinear out-
comes. Our study is at least informative in part, since our
analysis used one trial focused on patellofemoral OA and
the other unselected knee OA patients.
The analysis approach we used allowed us to test for dif-
ferences between outcomes. While we did observe some
statistically significant differences between outcomes, no
one outcome was clearly superior in both trials in terms of
sensitivity to change (see Supplementary Tables 5 and 6,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22823/abstract).
This is not an unexpected finding, given that all measures
should theoretically measure the same construct (pain, in
this study), and should therefore have at least similar effect
sizes. Given the similarity of these measures, it would
require either large differences in effects, or large sample
sizes to establish differences in outcomes. The trials we ana-
lyzed were neither designed nor powered to observe such
small differences between outcome measures, and therefore
the likelihood of observing truly significant differences was
unfortunately lacking. In the future, we would recommend
performing this type of analysis in larger real-world trials.
Another potential limitation is that use of a single question
focused on pain with 1 activity may compromise content
validity, the evaluation of all of the impacts of a disease.
If a patient nominates an activity in which pain is amelio-
rated completely following treatment, then that activity
experiences floor effects, especially in a long-term study. For
example, a treatment that fully cures pain from sitting to
standing after initial application would register no change at
the subsequent followup, highlighting the importance of the
activity that the patient selects. In a similar vein, in longer-
term followup, activities that were selected by participants
at baseline may become less relevant as the pattern of dis-
ability changes. Allowing the patient to alter the selected
activity should it reach the minimal score is complex, partic-
ularly if patients select an activity that is not in the same
“dimension.” For example, a patient nominates “pain when
getting up from sitting,” then improves in the trial, and then
switches to “pain when doing exercise classes.” These 2
activities are acceptable on their own, at each visit, but it is
unclear how comparable they are on a unidimensional scale,
which is a limitation of the proposed flexible approach.
CAT methods sidestep this issue through prior calibration of
item-bank questions to ensure that they all measure 1 com-
mon metric. A drawback of the VASNA used in BRACE and
TASK is that it is susceptible to floor effects when used in a
trial that 1) has a large pain effect, and 2) is very long term;
these are not uncommon properties of OA trials.
The VASNA uses a visual analog score to collect continu-
ous data on pain. Some groups have reported that partici-
pants find VAS difficult to understand, leading to decreased
response rates when compared to a Likert scale or NRS (24).
Indeed, some trials have investigated this issue as a primary
study aim (25). Perhaps in the future, following the recom-
mendations of the Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials group (9), the VASNA
could be applied using an NRS (in effect, an NRSNA), which
would have the advantages of both sensitivity and increased
response rates.
In conclusion, we suggest that in knee OA studies patient-
preference instruments may offer sensitivity to change and
the opportunity to detect treatment effects that might be
missed by conventional fixed instruments. Our work needs
to be corroborated in other studies.
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